Biolegend, 505805, FITC anti-mouse IFN-γ Antibody, 25μg

IFN-γ is a potent multifunctional cytokine which is secreted primarily by activated NK cells and T cells. Originally characterized based on anti-viral activities, IFN-γ also exerts anti-proliferative, immunoregulatory, and proinflammatory activities. IFN-γ can upregulate MHC class I and II antigen expression by antigen-presenting cells.
25μg
Verified Reactivity: Mouse
Antibody Type: Monoclonal
Host Species: Rat
Immunogen: E. coli-expressed, recombinant mouse IFN-γ
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation: The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration: 0.5 mg/ml
Storage & Handling: The IFN-γ antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: ICFC - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.
Excitation Laser: Blue Laser (488 nm)
Application Notes: ELISA1-4,11,14 or ELISPOT5 Detection: The biotinylated XMG1.2 antibody is useful as a detection antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with purified R4-6A2 antibody (Cat. No. 505702/505706) as the capture antibody and recombinant mouse IFN-γ (Cat. No. 575309) as the standard. ELISA or ELISPOT Capture: The purified XMG1.2 antibody is useful as a capture antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with biotinylated R4-6A2 antibody (Cat. No. 505704) as the detection antibody and recombinant mouse IFN-γ (Cat. No. 575309) as the standard. The LEAF™ purified antibody is suggested for ELISPOT capture (Cat. No. 505812). Flow Cytometry7,8,12,13,16: The fluorochrome-labeled XMG1.2 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IFN-γ-producing cells within mixed cell populations. Neutralization1-3,9,10: The XMG1.2 antibody can neutralize the bioactivity of natural or recombinant IFN-γ. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of mouse IFN-γ bioactivity in vivo and in vitro (Cat. No. 505812). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 505834) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg). Additional reported applications (for the relevant formats) include: Western blotting, immunohistochemical staining of frozen tissue sections6,22,23, and immunocytochemistry. Note: For testing mouse IFN-γ in serum, plasma or supernatant, BioLegend's ELISA Max™ Sets (Cat. No. 430801 to 430806) are specially developed and recommended.
Application References(PubMed link indicates BioLegend citation): Abrams J, et al. 1992. Immunol. Rev. 127:5. (ELISA, Neut) Sander B, et al. 1993. J. Immunol. Meth. 166:201. (ELISA, Neut) Abrams J, et al. 1995. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.20. (ELISA, Neut) Yang X, et al. 1993. J. Immunoassay 14:129. (ELISA) Klinman D, et al. 1994. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.19. (ELISPOT) Sander B, et al. 1991. Immunol. Rev. 119:65. (IHC) Ferrick D, et al. 1995. Nature 373:255. (FC) Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed Peterson KE, et al. 2000. J. Virol. 74:5363. (Neut) DeKrey GK, et al. 1998. Infect. Immun. 66:827. (Neut) Dzhagalov I, et al. 2007. J. Immunol. 178:2113. (ELISA) Lawson BR, et al. 2007. J. Immunol. 178:5366. (FC) Lee JW, et al. 2006. Nature Immunol. 8:181. (FC) PubMed Xu G, et al. 2007. J. Immunol. 179:5358. (ELISA) PubMed Montfort M, et al.2004. J. Immunol. 173:4084. PubMed Haring JS, et al. 2008. J. Immunol. 180:2855. (FC) PubMed Jordan JM, et al. 2008. Infect Immun. 76:3717. PubMed Tonkin DR, et al. 2008. J. Immunol. 181:4516. PubMed Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed Cui Y, et al. 2009. Invest. Ophth. Vis. Sci. 50:5811. (FC) PubMed Mykkanen OT, et al. 2014. PLoS One. 9:114790. PubMed Yokogawa M, et al. 2013. Mol. Carcinog. 52:760. (IHC) Mottram PL, et al. 1998. J Immunol. 161:602. (IHC)
Product Citations: Chuang H, et al. 2014. Nat Commun. 5:4602. PubMed Li B, Schmidt N 2016. PLoS One. 11: 0162427. PubMed Logan K Smith et al. 2018. Immunity. 48(2):299-312 . PubMed Laura C Burzynski et al. 2019. Immunity. 50(4):1033-1042 . PubMed Wang X, et al. 2019. Cell Res. 29:787. PubMed Belk JA, et al. 2022. Cancer Cell. 40:768. PubMed Zhao L, et al. 2022. Oncogene. 41:4200. PubMed Konjar S, et al. 2022. Proc Natl Acad Sci U S A. 119:e2202144119. PubMed Sanmarco LM, et al. 2022. Nature. 611:801. PubMed Deák P, et al. 2022. Cell Rep. 41:111563. PubMed Zhao Q, et al. 2023. Signal Transduct Target Ther. 8:40. PubMed Li G, et al. 2023. Cell Death Dis. 14:185. PubMed Fan NW, et al. 2023. FASEB J. 37:e22855. PubMed Tang C, et al. 2023. Nat Commun. 14:1493. PubMed Ye S, et al. 2023. Front Oncol. 13:1202750. PubMed Chen N, et al. 2021. Front Immunol. 12:756423. PubMed Yamazaki S, et al. 2022. Mucosal Immunol. :. PubMed Schenkel JM, et al. 2021. Immunity. 54:2338. PubMed D'Angeli V, et al. 2022. Eur J Immunol. 52:1058. PubMed Wang H, et al. 2022. Immunol Cell Biol. 100:547. PubMed Zhao Z, et al. 2022. Adv Sci (Weinh). 9:e2201293. PubMed Lin G, et al. 2022. Int J Immunopathol Pharmacol. 36:3946320221117933. PubMed Balood M, et al. 2022. Nature. 611:405. PubMed Xu H, et al. 2022. Aging Dis. 13:1875. PubMed Wang R, et al. 2023. iScience. 26:105954. PubMed Scherer S, et al. 2023. Nat Immunol. 24:501. PubMed Kim EH, et al. 2020. Elife. 9:00. PubMed Zhu C, et al. 2018. Sci Rep. 5.113194444. PubMed Onodera A, et al. 2017. J Immunol. 10.4049/jimmunol.1602129. PubMed Yu Y, et al. 2022. iScience. 25:105004. PubMed Di Martile M, et al. 2020. J Immunother Cancer. 8:. PubMed Ford K, et al. 2020. Cancer Res. 80:1846. PubMed Misumi I et al. 2019. Cell Rep. 27(5):1387-1396 . PubMed Kenichi Shimada et al. 2018. Immunity. 49(5):873-885 . PubMed Gupta SS, et al. 2019. Cell Rep. 29:1862. PubMed Magen A, et al. 2019. Cell Rep. 29:3019. PubMed Hewitson JP, et al. 2020. J Immunol. 204:2949. PubMed Gao Y, et al. 2020. Nat Cell Biol. 1064:22. PubMed Weigelin B, et al. 2015. Proc Natl Acad Sci U S A. 112:7551. PubMed Yang W, et al. 2020. Nat Commun. 3.553472222. PubMed Volpedo G, et al. 2022. NPJ Vaccines. 7:32. PubMed Isakova-Sivak I, et al. 2020. Vaccines (Basel). 8:00. PubMed Zhao B, et al. 2021. Cell Reports. 36(3):109401. PubMed Bartleson JM, et al. 2020. Nat Immunol. 1384:21. PubMed Misumi I et al. 2019. Cell Rep. 27(2):514-524 . PubMed Cai B, et al. 2021. Mol Cancer. 20:165. PubMed Sehnert B, et al. 2022. Front Immunol. 13:921488. PubMed Wang Z, et al. 2020. Autophagy. 1:. PubMed Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed Ni P, et al. 2014. J Immunol . 193:1778. PubMed Larena M, et al. 2011. J Virol. 85:5446. PubMed Chao CC, et al. 2020. Cell. 179(7):1483-1498.e22.. PubMed Lu Y, et al. 2020. Cell. 180(6):1081-1097. PubMed Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed Sasaki K, et al. 2019. Nat Commun. 10:3878. PubMed Yang X, et al. 2019. Oncotarget. 10:4180. PubMed Khan IM, et al. 2021. Immunohorizons. 5:703. PubMed Sato Y, et al. 2021. J Clin Invest. Online ahead of print. PubMed Li H, et al. 2021. Nat Commun. 12:2773. PubMed Ontiveros-Padilla L, et al. 2021. Microorganisms. 9:. PubMed Wei F, et al. 2014. Cancer Res. 74:5989. PubMed Montel-Hagen A, et al. 2020. Cell Rep. 33:108320. PubMed Alessandrini F, et al. 2019. Oncogene. 38:4467. PubMed Sophie Thiemann et al. 2017. Cell host & microbe. 21(6):682-694 . PubMed He J, et al. 2020. Cell Reports. 29(9):2718-2730.e6.. PubMed Khakhum N, et al. 2021. NPJ Vaccines. 6:72. PubMed Zhao F, et al. 2022. Front Immunol. 13:873720. PubMed Ni P, et al. 2014. Mol Immunol. 62:199. PubMed Dar HY, et al. 2018. Sci Rep. 8:2503. PubMed Pu Y, et al. 2022. Transl Psychiatry. 12:223. PubMed Li Y, et al. 2015. J Nutr Biochem. Available online 8 August 2015. PubMed Dar HY, et al. 2018. Bone Rep. 8:46. PubMed Nika L, et al. 2019. Vaccines (Basel). 7. PubMed Hu Q, et al. 2018. Nat Biomed Eng. 0.660416667. PubMed Du Y, et al. 2022. Nat Commun. 13:231. PubMed Zhang L, et al. 2022. Front Immunol. 13:828263. PubMed Pardy RD, et al. 2021. Nat Commun. 12:4051. PubMed Gudgeon N, et al. 2022. Cell Rep. 40:111193. PubMed Stutz MD, et al. 2021. Immunity. 54(8):1758-1771.e7. PubMed Tartey S, et al. 2021. Cancer Research. 81(9):2358-2372. PubMed Cheng Y, et al. 2020. PLoS Pathog. 16:e1008569. PubMed Crooks SD, et al. 2022. Immunohorizons. 6:705. PubMed Ren Y, et al. 2022. J Immunother Cancer. 10:. PubMed Chung NH, et al. 2022. Vaccine. 40:574. PubMed Baier FA, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:745. PubMed Gao X, et al. 2010. Mol Immunol. 47:2397. PubMed Kedzierski L, et al. 2014. PLoS Pathog. 10:1004134. PubMed White C, et al. 2015. J Immunol. 194:697. PubMed Sood S, et al. 2016. J Immunol. 197: 429 - 440. PubMed Deerhake ME, et al. 2021. Immunity. 54(3):484-498.e8. PubMed Ren W, et al. 2018. Mucosal Immunol. 12:531. PubMed Guo C, et al. 2017. Methods Mol Biol. 1709:345. PubMed Sun C, et al. 2022. J Adv Res. 35:71. PubMed Shen M, et al. 2022. Nat Cancer. 3:60. PubMed Liu B, et al. 2022. Mol Med Rep. 26:. PubMed Ni J, et al. 2020. Immunity. 52(6):1075-1087.e8. PubMed Vardhana SA, et al. 2020. Nat Immunol. 1.584722222. PubMed Pinget G, et al. 2016. Immunol Cell Biol. 10.1038/icb.2016.48. PubMed Gagnon JD, et al. 2019. Cell Rep. 28:2169. PubMed Ding P, et al. 2022. Bone Res. 10:42. PubMed Yang BH, et al. 2020. Cell Reports. 27(12):3629-3645.e6.. PubMed Montfort M, et al. 2004. J Immunol. 173:4084. PubMed Li Y, et al. 2021. Elife. 10:. PubMed Evgin L, et al. 2022. Sci Transl Med. 14:eabn2231. PubMed Gomez S, et al. 2022. J Immunother Cancer. 10:. PubMed Wu B, et al. 2021. Immunity. 54(2):308-323.e6. PubMed Lebrun A, et al. 2015. J Immunol. 195: 4358 - 4368. PubMed Li Z, et al. 2022. Nat Commun. 13:6321. PubMed Olivo Pimentel V, et al. 2021. J Immunother Cancer. 9:. PubMed Wang Y, et al. 2021. Nat Commun. 12:4964. PubMed Miyauchi E, et al. 2020. Nature. 585:102. PubMed Brenndörfer E, et al. 2014. J Immunol. 192:1671. PubMed M H, et al. 2016. Open Bio. 6: 150208. PubMed Fernández-Orth J, et al. 2020. Eur J Immunol. . PubMed Nakornpakdee Y, et al. 2018. Asian Pac J Allergy Immunol. 36:265. PubMed Zhang X, et al. 2021. Nat Commun. 12:4536. PubMed Harb H, et al. 2020. Nat Immunol. 1359:21. PubMed Yuan C, et al. 2015. Biochem Biophys Res Commun. 464: 249-255. PubMed Lee J, et al. 2007. Nat Immunol. 8:181. PubMed McCauley ME, et al. 2020. Nature. 585(7823):96-101. PubMed Moufarrij S, et al. 2020. Sci Rep. 10:3470. PubMed Li N, et al. 2022. Nat Commun. 13:7281. PubMed He X, et al. 2021. J Immunother Cancer. 9:. PubMed Zhu E, et al. 2014. J Immunol. 192:5599. PubMed Takahashi T, et al. 2017. J Exp Med. 10.1084/jem.20160247. PubMed Dai X, et al. 2021. Molecular Cell. 81(11):2317-2331.e6. PubMed Sade–Feldman M, et al. 2018. Cell. 175:998. PubMed Kong XF, et al. 2018. Nat Immunol. 19:973. PubMed Field CS, et al. 2020. Cell Metab. 31:422. PubMed Huang LJ, et al. 2021. Immunity. 54(8):1728-1744.e7. PubMed Ukidve A, et al. 2020. Proc Natl Acad Sci U S A. 117:17727. PubMed Zeng J, et al. 2020. Int J Biol Sci. 1.939583333. PubMed Ding Z, et al. 2017. Sci Rep. 10.1038/s41598-017-12488-z. PubMed Hao L, et al. 2021. Br J Pharmacol. 178:4726. PubMed Li J, et al. 2012. Arthritis Rheum. 64:1098. PubMed Zamora-Chimal J, et al. 2017. Immunobiology. 222(2):454-462. PubMed Wang J, et al. 2020. Cell. 183(7):1867-1883.e26. PubMed Sartorius R, et al. 2018. Front Immunol. 1.413888889. PubMed Dai B, et al. 2021. Cell Reports Medicine. 2(8):100381. PubMed Angelou CC, et al. 2020. Frontiers in Immunology. 2.586805556. PubMed Bing Wu et al. 2018. Immunity. 49(5):886-898 . PubMed Aggarwal N, et al. 2021. Cell Rep. 37:110170. PubMed Tseng SH, et al. 2021. J Biomed Sci. 28:63. PubMed Nakazawa S, et al. 2020. Sci Rep. 10:14559. PubMed Ren X, et al. 2021. Cell Death Dis. 12:484. PubMed
RRID: AB_315399 (BioLegend Cat. No. 505805) AB_315400 (BioLegend Cat. No. 505806)
Structure: Cytokine; dimer; 40-80 kD (Mammalian)
Bioactivity: Antiviral/antiparasitic activities; inhibits proliferation; enhances MHC class I and II expression on APCs
Cell Sources: CD8+ and CD4+ T cells, NK cells
Cell Targets: T cells, B cells, macrophages, NK cells, endothelial cells, fibroblasts
Receptors: IFN-γRα (CDw119) dimerized with IFN-γRβ (AF-1)
Cell Type: Tregs
Biology Area: Cell Biology, Immunology, Neuroinflammation, Neuroscience
Molecular Family: Cytokines/Chemokines
Antigen References: 1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego. 2. De Maeyer E, et al. 1992. Curr. Opin. Immunol. 4:321. 3. Farrar M, et al. 1993. Annu. Rev. Immunol. 11:571. 4. Gray P, et al. 1987. Lymphokines 13:151.
Regulation: Upregulated by IL-2, FGF-basic, EGF; downregulated by 1-α-25-Dihydroxy vitamin D3, dexamethasone
Gene ID: 15978
UniProt: View information about IFN-gamma on UniProt.org
Clone: XMG1.2
Regulatory Status: RUO
Other Names: Interferon-γ, Immune interferon, Type II interferon, T cell interferon, Macrophage-activating factor (MAF)
Isotype: Rat IgG1, κ